Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibition
Open Access
- 2 February 2022
- journal article
- research article
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 438, 115905
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Drug-induced Valvulopathy: An UpdateToxicologic Pathology, 2010
- Critical roles of the TGF-β type I receptor ALK5 in perichondrial formation and function, cartilage integrity, and osteoblast differentiation during growth plate developmentDevelopmental Biology, 2009
- Poor vessel formation in embryos from knock-in mice expressing ALK5 with L45 loop mutation defective in Smad activationLaboratory Investigation, 2009
- Signaling via the Tgf-β type I receptor Alk5 in heart developmentDevelopmental Biology, 2008
- Association of Inhalation Toxicologists (AIT) Working Party Recommendation for Standard Delivered Dose Calculation and Expression in Non-Clinical Aerosol Inhalation Toxicology Studies with PharmaceuticalsInhalation Toxicology, 2008
- Compensatory signalling induced in the yolk sac vasculature by deletion of TGFβ receptors in miceJournal of Cell Science, 2007
- Inhibition of ALK5 Signaling Induces Physeal Dysplasia in RatsToxicologic Pathology, 2007
- Activin Receptor-like Kinase (ALK)1 Is an Antagonistic Mediator of Lateral TGFβ/ALK5 SignalingMolecular Cell, 2003
- Normal B lymphocyte development but impaired T cell maturation in CD45-Exon6 protein tyrosine phosphatase-deficient miceCell, 1993
- Profound block in thymocyte development in mice lacking p56lckNature, 1992